Frequency Of Sexual Dysfunction Research Articles

DIABETES-RELATED SEXUAL DYSFUNCTION AND ITS ASSOCIATION WITH MICROVASCULAR COMPLICATIONS: A STUDY FROM TERTIARY CARE CENTER IN SOUTH KERALA

Objectives: (1) The objective of this study was to determine the frequency of sexual dysfunction (SD) among patients with Type 2 diabetes mellitus attending the General Medicine and Endocrinology Department at a tertiary care center in south Kerala. (2) To assess the relationship between erectile dysfunction and the microvascular consequences of Type 2 diabetes. (3) To correlate SD with glycemic status. Methods: One hundred and twenty patients with Type 2 diabetes at a tertiary care center in south Kerala participated in the cross-sectional study. A questionnaire was employed to document demographic and glycemic status. The assessment tools utilized included the International Index of Erectile Function for male and the Female Sexual Function Index (FSFI) scoring questionnaire for females. The statistical analysis employed included unpaired t-tests for students and tests assessing the equality of proportions. Results: About 65% of patients with diabetes mellitus had SD. About 46% of female participants and 78.6% of male participants in the study population had SD. Duration of diabetes, poor glycemic status, and microvascular complications correlated with SD. Conclusion: SD is frequent in patients with Type 2 diabetes mellitus. Glycemic control determines the development of SD. It is advisable to screen patients with Type 2 diabetes mellitus for SD as a proactive measure for early intervention and management.

(179) Sexual Dysfunctions in Infertile Tunisian Women

Abstract Introduction Once perceived as a source of pleasure and enjoyment, sexuality has evolved for infertile couples, focusing primarily on a purely procreative objective. Infertility has a direct impact on a woman's sex life, calling into question her femininity and causing significant alterations in the components of her sexual response. Objective The aims of our study were to assess the frequency of sexual dysfunction in Tunisian women facing infertility and to identify the aspects of their sexuality most affected. Methods This was a prospective, cross-sectional, and descriptive study, including a sample of 200 Tunisian infertile women, followed up in a Tunisian Assisted reproduction center over a three-month period, from November 24, 2022 to February 24, 2023. To assess the different dimensions of sexuality in infertile women, we used the Arabic version of the FSFI (female sexual function index) Results The mean age of our women was 30 ± 4 years. The majority had a university educational level (80%), an urban origin (87%), an average socio-economic level (63%), and no medical or gynecological surgery history (62%). Most partners (67%) had no sexual dysfunction (SD). The most frequent male SD was premature ejaculation, observed in 14% of cases. As regards the etiology of infertility, most cases were classified as unexplained (28%), while the remainder were linked to female causes, dominated by PCOS (40%). The majority of women had initially discussed the subject of sexuality (72%) with their partners. In our sample, the mean FSFI score was 20.74, with extremes ranging from 2 to 35.4. The prevalence of female sexual dysfunction (FSD) was 82%. The areas most affected were sexual satisfaction (50%), reaching orgasm (45%), as well as lubrication (44%) and arousal (44%). Lower educational level, secondary infertility, contraceptive use, and a long history of fertility treatment as well as the presence of sexual dysfunction in the male partner, were found to be associated with sexual dysfunction in women suffering from infertility, yet no significant correlation was established. Conclusions Infertility is associated with high rates of sexual dysfunction. Thorough counseling and continuing support of infertile women is therefore indicated. Disclosure No.

Sexual dysfunction in men with young onset Parkinson's disease.

Sexual dysfunction (SD) is a common, yet under-reported non-motor symptom of PD. Common sexual symptoms among male PD patients include erectile dysfunction, premature ejaculation, and decreased sexual desire. Few research papers have examined sexual dysfunction in PD, especially in YOPD male patients, and there is no Indian research study on sexual dysfunction in YOPD. In this study, we determined the frequency of sexual dysfunction in men with YOPD, and its correlation with other motor and NMS. This prospective cross-sectional study was conducted on YOPD males who presented to the Department of Neurology, NIMHANS, Bangalore, India, from May 2021 to April 2023. The diagnosis of YOPD was made based on MDS criteria for IPD 2015. Sexual functions were evaluated by ASEX, PEDT, QUIP-RS, and sex hormone assay. The patients also underwent other motor and non-motor assessments. Statistical analysis was done using SPSS version 22.0. The study was funded by the PDMD fund. This study included 62 male YOPD patients. The mean age of cases was 44.74 ± 8.54years. The mean duration of symptoms was 8.45 ± 6.23years. 43.5% of the cases of PD were Akinetic rigid type. By ASEX Score grading, 46.8% of the cases had erectile dysfunction and 71% of the cases of YOPD had premature ejaculation by PEDT Score grading. 9.7% of the cases had hypersexuality by QUIP-RS.Duration of YOPD was a better predictor of Erectile Dysfunction and premature ejaculation when compared with other variables. SD was related to anxiety and depression and it had a negative impact on the patient's health-related quality of life (HR-QoL). SD should be investigated and treated as an integral part of the neurological assessment in YOPD.

COVID-19'lu Kadınların İyileşme Sonrası Cinsel İşlevleri ve İlişkili Faktörler

This study was conducted to investigate the sexual function status and related factors in women after contracting COVID-19. The study comprised 261 women who had been infected with COVID-19. Data were collected using the Personal Information Form, the Female Sexual Function Scale, and the State-Trait Anxiety Inventory. Sub-dimension scores for desire (3.80 ± 1.16, 3.66 ± 1.17), arousal (4.25 ± 1.40, 4.11 ± 1.41), orgasm (4.36 ± 1.25, 4.29 ± 1.26), and sexual satisfaction (4.50 ± 1.49, 4.40 ± 1.49) in women, as well as the Female Sexual Function Scale total score (26.50 ± 6.79, 26.00 ± 6.93), decreased following COVID-19 infection. Moreover, the frequency of weekly intercourse decreased (2.78 ± 0.90; 2.60 ± 0.92) compared to the pre-infection levels, and the frequency of sexual dysfunction increased (FSFI < 26 = 38.7%, 46.0%). In this study, advanced age, high body mass index (BMI) value, low education, income level, unemployment, smoking, lack of physical activity, anxiety, decreased coital frequency, and COVID-19 infection were identified as risk factors for sexual dysfunction. There was no significant relationship between the time elapsed after recovery from COVID-19 and sexual function. In conclusion, this research suggests that COVID-19 infection may lead to sexual dysfunction in women. Based on these research findings, health practitioners should assess the sexual health of female patients who have had COVID-19 infections, ensuring that women feel comfortable discussing their sexual health issues and referring them to appropriate treatment and counseling services when needed.

A Study of Sexual Dysfunction and Quality of Life in Female Patients on Selective Serotonin Reuptake Inhibitor (SSRI)

Context: Sexual dysfunction is one of the most common and disconcerting side effect during treatment with Selective serotonin reuptake inhibitors (SSRIs). Sexual side effects from these medications have significant impact on self esteem, quality of life and can lead to non compliance and relapse in long term treatment. Aims: To study prevalence, severity of sexual dysfunction and its possible association with quality of life in female patients on treatment with SSRI for depression and anxiety. Materials and Methods: This was an observational, cross sectional, single-centre study. Hundred consecutive female patients who were sexually active, on SSRIs for six weeks or more were recruited. Diagnosis of Major depressive disorder (MDD), Anxiety disorders and female sexual dysfunction was done by clinician administered interview as per Diagnostic and Statistical Manual of mental disorders (DSM 5). The patients were further assessed for demographic details, CSFQ-F-C, HAM-D, HAM-A and WHOQOL-BREF scales for sexual dysfunction, depression, anxiety and quality of life respectively. p value of <0.05 was considered to be statistically significant. Results: Prevalence of sexual dysfunction was 84%. Patients with sexual dysfunction scored significantly lower value in social relationships (p= 0.0002) and environment (p= 0.033) domains of quality of life. Frequency of sexual dysfunction among patients on fluoxetine was 86.20%, on escitalopram was 86.76% and on sertraline was 66.6%. Frequency of sexual dysfunction was more with higher dose of SSRIs. Conclusions: Patients on various SSRIs experienced sexual dysfunction and had poor quality of life. Frequency of sexual dysfunction was more with higher doses of SSRIs. Keywords: Sexual dysfunction, Selective serotonin reuptake inhibitors, Depression, Anxiety, quality of life.

The Frequency and Predictors of Sexual Dysfunction Among People Living with HIV/AIDS.

The frequency of sexual dysfunctions reported by HIV/AIDS patients is significantly higher than that of their peers. Sexual dysfunction and its predictors may result in increased viral loads, worsening HIV infection, and infectivity. To mitigate its consequences, appropriate evaluation and intervention are required. A cross-sectional study design was conducted among 336 HIV/AIDS-positive individuals at one hospital in southwest Ethiopia. To assess sexual dysfunctions, a tool called the Changes in Sexual Functioning Questionnaire (CSFQ-14) was used. Data analysis was done with SPSS version 20. Bivariate and multivariable logistic regressions were used to identify independent predictor variables, and statistical significance was declared at a p-value of <0.05. 98.53% of the sample completed the questionnaire accordingly. The frequency of SD was 72.0% (95% CI = 67.4-77.0). The frequency of SD was reported to be more prevalent among males (76.8% (95% CI = 70.6-81.6)) than that of females (66.2% (95% CI = 59.5-73.5)). Among the domains of sexual dysfunction, sexual pleasure problems (96.70%, (95% CI: 94.60-98.50)) were the higher figure of SD, and sexual desire problems (82.40%, (95% CI: 78.60-86.60)); were the least prevalent sexual dysfunctions. Predictors of the SD were age, social anxiety, nicotine use, poor sleep quality, and time of resuming ART medication. The frequency of SD was 72.0%. Predictors of the SD were age, social anxiety, nicotine use, poor sleep quality, and time of resuming ART medication.

Sarcopenic obesity is not associated with sexual dysfunction in older adults: a cross-sectional study

Background This study aimed to investigate the frequency of sexual dysfunction (SD) and the association between SD and body composition abnormalities, such as sarcopenia, obesity, and sarcopenic obesity. Methods Older adults (≥65 years) were included. Sarcopenic obesity was diagnosed by using newly defined ESPEN-EASO diagram. Sarcopenia was diagnosed according to the European Working Group on Sarcopenia in Older People criteria. Obesity was defined using the fat percentile cut-offs suggested by ESPEN-EASO. SD was determined by Arizona Sexual Experience Scale (ASEX). Results Two-hundred and sixty-seven volunteers (64.4% female, mean age 73.63 ± 6.22 years) participated in this study. One-hundred seventy-eight individuals (66.7%) had SD. It was present in 83.1% and 36.8% of the females and males, respectively (p < 0.0001). There was no association between SD and sarcopenia alone (OR: 1.359, 95% CI: 0.650–2.838, p = 0.415) or obesity alone (OR: 0.986, 95% CI: 0.543–1.791, p = 0.963). Sarcopenic obesity was significantly associated with SD (OR: 9.116, 95% CI: 1.173–70.851, p = 0.035). However, this significance was lost after the model was adjusted for gender, marital status, and comorbidities (OR: 4.676, 95% CI: 0.578–37.801, p = 0.148). Conclusions SD was present in 66.7% of the older adults and was not associated with sarcopenia, obesity, or sarcopenic obesity. Further longitudinal studies are needed on this topic.

Panik bozukluk hastalarında cinsel işlev bozukluğu sıklığının cinsiyet açısından karşılaştırması

Purpose: The aim of this study is to evaluate the frequency of sexual dysfunction in male and female panic disorder (PD) patients and to make a comparison between genders.&#x0D; Materials and Methods: A total of 57 cases, including 33 females aged 36±6 years and 24 males aged 35±7 years, who were sexually active, did not use psychotropic drugs, with primary diagnosis of PD according to DSM-5, were included in the study. Individual information collection forms and the Arizona Sexual Experiences Scale (ASEX) were applied to all cases, and sexual dysfunctions (SD) were questioned.&#x0D; Results: According to the suggested cut-off score of the Turkish version of the Arizona Sexual Experiences Scale, 77.2% of all participants had SD. SD was detected in 81.8% of women and 70.8% of men. There was a significant difference between men and women in terms of ASEX total scores. There was no significant difference between men and women in terms of sexual desire and orgasm satisfaction. Sub-dimension scores of arousal, lubrication/erection, and reaching orgasm were significantly higher in females. Sexual reluctance was the most common in both genders, with 30.4% of women and 36.5% of men.&#x0D; Conclusion: Sexual dysfunction is common among PD patients. Sexual reluctance is the most common in male and female patients with PD. Arousal and orgasm problems are more common in female PD patients than in male PD patients.

Frequency of sexual dysfunction in outpatients with severe mental illness in Greece.

Patients with psychosis can develop sexual dysfunction, which may be related to the disease itself, psychosocial factors, somatic comorbidities, and the use of psychotropic medication. We aimed to investigate the type and frequency of sexual dysfunction in patients diagnosed with schizophrenia or bipolar disorder in order to assess the side effects of antipsychotics in sexual function. This is a multicenter, cross-sectional study, involving patients diagnosed with schizophrenia (79.3%) or bipolar disorder (20.7%) treated in the Department of Psychiatry and Community Mental Health Centers from November 2018 to December 2019. Patients were enrolled in the study after signed informed consent. Demographic and clinical data were collected from patients through a semi-structured interview. The Antipsychotics and Sexual Functioning Questionnaire (ASFQ) was administered to assess sexual function. A total of 87 outpatients on antipsychotics were recruited in the study. The mean age was 43.6 years, while the mean duration of the disease was 16.9 years. Overall, only 9.1% of patients spontaneously reported sexual dysfunction. Patients treated with oral first-generation antipsychotics had more difficulties in achieving orgasm and decreased erection capacity. In contrast, patients treated with oral second-generation antipsychotics had decreased ejaculation capacity. Patients on antipsychotic combination therapy were associated with higher rates of sexual anhedonia. These results suggest that sexual dysfunction is a side effect of antipsychotic treatment, which was spontaneously rarely reported by patients. It seems essential to obtain a psychosexual clinical history before initiating antipsychotic treatment to evaluate following changes and adopt an individualized strategy to manage sexual dysfunction induced by antipsychotics.

Prevalence and correlates of sexual dysfunction among patients with schizophrenia spectrum disorder on antipsyhotic medications in Maiduguri, Northeastern Nigeria.

Despite the importance of a satisfying sexual life, most patients with schizophrenia spectrum disorders do not discuss sexual issue with their clinicians. The current study seeks to determine the prevalence and socio-clinical correlates of sexual dysfunction among patients with schizophrenia spectrum disorders receiving typical and atypical antipsychotic medications. The second objective is to determine the frequency and correlates of specific sexual dysfunction (desire, arousal, erection/lubrication and orgasm) by gender and drug type using the Arizona Sexual Experience Scale. This cross-sectional study used standardized structured interviewer based survey to assess sexual dysfunction among patients with schizophrenia that are both sexually active and inactive at a tertiary hospital in Maiduguri from December 2020 to April 2021. Participants were also assayed for prolactin using ELISA Kit for a possible association with sexual dysfunction. The overall prevalence of sexual dysfunction among patients with schizophrenia spectrum disorder receiving antipsychotics was 34% with patients on typical and atypical antipsychotics reporting rates of 36.8% and 24.6%, respectively. Among the typical and atypical antipsychotics, patients receiving haloperidol (40.3%) and risperidone (37.5%) reported a relatively higher frequency of sexual dysfunction compared to those receiving clozapine (18.2%). Independent correlates of sexual dysfunction were: female gender (OR = 1.89, 95% CI = 1.17-3.06; P = .010), being unmarried (OR = 1.51, 95% CI = 1.17-1.96; P = .001), pseudoparkinsonism (OR = 1.66, 95% CI = 1.02-2.69; P = .008), prolactin (OR = 2.15, 95% CI = 1.34-3.43; P = .001) and severity of illness (OR = 1.34, 95% CI = 1.03-1.75; P = .030). Sexual dysfunction is prevalent among patients with schizophrenia spectrum disorder receiving either typical or atypical antipsychotics.

Association of sexual dysfunction according to DSM-5 diagnostic criteria with avoidance of and discomfort during sex in a population-based sample.

Sexual dysfunction frequencies and diagnostic indicators among older populations are relevant for public health measures, but evidence from large population-based studies is still scarce. To determine sexual dysfunction frequencies for women and men according to the Diagnostic and Statistical Manual of Mental Disorders (fifth edition; DSM-5) among 45- to 74-year-old participants of the population-based Hamburg City Health Study and the factors associated with sexual dysfunction diagnoses. We determined sexual dysfunction frequencies according to the DSM-5 and the factors associated with sexual dysfunction diagnoses (quality/avoidance of and discomfort during sex) among 45- to 74-year-olds from 7786 participants of the population-based Hamburg City Health Study. We analyzed cross-sectional self-report questionnaire data collected between 2016 and 2019 using descriptive statistics, comparative tests (Fisher test, Mann-Whitney U test), and logistic regression. Outcomes included sexual dysfunction frequencies - specifically, sexual difficulties experienced frequently or more often, over at least six months in the last year, causing severe or very severe distress, and not associated with physical health or relationship problems - and items on quality/avoidance of and discomfort during sex. Participants' median age was 62.0 years (IQR,14) and 51.1% were women. The frequency of sexual dysfunction according to the DSM-5 was 9.3% (95% CI, 8.3%-10.4%) in women and 6.2% (95% CI, 5.4%-7.1%) in men, with women's sexual interest/arousal and men's erectile disorder being most common. Sexual dysfunction rates increased with age: whereas complaints were more frequent among women than men in the younger groups, participants aged ≥65 years with a sexual dysfunction were more often men. Quality/avoidance of and discomfort during sex were significantly associated with a diagnosis of sexual dysfunction. Results suggest that sexual dysfunction caused by other than physical health or relationship factors is important to consider in this population. In addition, the avoidance of, perceived quality of, and discomfort during sex serve as valuable diagnostic indicators for the presence of sexual dysfunction. This study draws on robust data from a large sample to give valuable insight on the frequency of sexual difficulties and dysfunctions as defined by DSM-5 criteria. Limitations represent the restriction to self-report questionnaire data, the focus on participants living in a metropolitan area, and the lack of experience of sexual difficulties due to a lack of sexual activity not being taken into account. The study provides estimates for DSM-5 sexual dysfunction frequencies among Germans from a metropolitan area and points to the diagnostic value of age-related changes as well as the quality/avoidance of and discomfort during sex.

Sexual Dysfunctions in Females with Parkinson's Disease: A Cross-Sectional Study with a Psycho-Endocrinological Perspective.

Background and Objectives: Normal human sexual functioning is a complex integration of an intact neuroanatomic substrate, vascular supply, a balanced hormonal profile, and a predominance of excitatory over inhibitory psychological mechanisms. However, sexual functioning in Parkinson's disease (PD) is often overlooked in clinical practice, especially in female patients. Materials and Methods: In this cross-sectional study, we have investigated the frequency of sexual dysfunction and the possible correlation with psycho-endocrinological factors in a sample of women with idiopathic PD. Patients were assessed using a semi-structured sexual interview, in addition to psychometric tools, including the Hamilton Rating Scale for Anxiety and for Depression and the Coping Orientation to the Problems Experiences-New Italian Version. Specific blood tests, including testosterone, follicle-stimulating hormone (FSH), luteinizing hormone (LH), estrogen E2, prolactin (PRL), and vitamin D3 were also evaluated. Results: Our results reported a statistical difference in sexual intercourse frequency before and after the onset of PD (p < 0.001). The percentage of women who complained about reduced sexual desire increased after diagnosis (52.7%) compared to the period before the onset of the illness (36.8%). The endocrinological profile in females with PD revealed statistically significant differences regarding testosterone (p < 0.0006), estradiol (p < 0.00), vitamin D3 (p < 0.006), and calcium (0.002). Depression (44% characterized by perceived feelings of anger and frustration during sexual intercourse) and anxiety symptoms (29.5% reported feelings of fear and anxiety for not satisfying the partner) with abnormal coping strategies (48.14% experienced feelings of anger and intolerance) were also found to be statistically significant. This study showed a high frequency of sexual dysfunction in female patients with PD, which correlated with sexual hormone abnormalities, mood/anxiety, and coping strategies alterations. This supports the idea that there is a need to better investigate the sexual function of female patients with PD to provide them with an adequate therapeutic approach and potentially improve quality of life.

Evaluation of Sexual Dysfunction and Related Factors in Iranian Men with Type 2 Diabetes: A Cross-Sectional Study

Objective: Recently, the association between sexual dysfunction (SD) and diabetes has been proven in various studies. The study aimed to determine the frequency of SD and identify risk factors related to SD in men with Type 2 diabetes mellitus (T2DM).&#x0D; Materials and Methods: The cross-sectional study was conducted on 114 men with T2DM who had referred to the Yazd Diabetes Center from 2019-2020. All of them filled out a standard questionnaire with a specified validity and reliability. The analysis was performed using ANOVA and Chi-square by SPSS, version 22 software.&#x0D; Results: The mean age of participants was 52.48 (±5.33). The SD frequency was 73.7%. The mean SD score was 17.89 (±12). There was a significant relationship between the total SD and neuropathy (P: 0.0001), retinopathy (P: 0.0001), nephropathy (P: 0.023), type of treatment (P: 0.0001), age (P: 0.0001) and addiction (P: 0.031). There was no significant relationship between the total SD score and hyperlipidemia (P: 0.371), hypertension (P: 0.683), Hb1Ac (P: 0.816), duration of diabetes (P: 0.101) and smoking (P: 0.29).&#x0D; Conclusion: Due to the high frequency of sexual dysfunction in men with T2DM, it is recommended that SD be considered as an important complication in these patients so that by identifying indicators related to this complication in patients with diabetes, sexual health clinics take the necessary measures to solve sexual problems in these patients.

IDF2022-0100 Frequency of sexual dysfunction in women with diabetes mellitus: A cross-sectional multicenter study

IDF2022-0100 Frequency of sexual dysfunction in women with diabetes mellitus: A cross-sectional multicenter study

Assessment of sexual life and social life in people with multiple sclerosis

Introduction: Multiple sclerosis is a debilitating condition that affects the central nervous system and is most common in young people. Over time, the relapses associated with the disease can cause damage, and within ten years of onset, half of patients may experience progressive symptoms. Unfortunately, once a patient enters a progressive stage, there is no longer any improvement or remission, though some patients may experience a longer period of stability.Objectives: The goal of this study is to examine the relationship between social and sexual life in patients with multiple sclerosis, considering the progressive nature of the disease, the fluctuating psychological impact, and the impact on their reproductive abilities.Methods: The study utilized the Multiple Sclerosis Quality of Life Questionnaire to assess the participants. This questionnaire measures quality of life by asking generic and specific questions related to multiple sclerosis, with a total of 18 items addressing specific needs such as fatigue, cognitive function, sexual function, daily activities, social interaction, and more.Results: The results indicated that most women with multiple sclerosis reported decreased lubrication, while men’s main concern was satisfying their partner. The majority of participants reported being neither satisfied nor dissatisfied with their sexual and social life. The frequency of sexual dysfunction was found to be higher in women with multiple sclerosis compared to the general population, with decreased libido being the most commonly reported issue. Individuals with primary progressive multiple sclerosis were found to have significantly increased problems with sexual function. Conclusion: This study found a correlation between social and sexual life for individuals with multiple sclerosis. As their social life worsened, their sexual life and reproductive capacity were also negatively impacted.

Sexual dysfunction on the background of antidepressant therapy

The review is devoted to the problem of sexual dysfunction caused by taking antidepressants. Sexual dysfunction is widespread, but it is not reported, and its impact on the quality of life and compliance of patients is underestimated. Partly because of its bidirectional association with depression, sexual dysfunction is difficult to diagnose. Possible mechanisms and risk factors associated with sexual dysfunction in patients with depression are considered. The data on the frequency of sexual dysfunction with the use of various antidepressants are given. Therapeutic strategies for sexual dysfunction associated with taking antidepressants are described. The advantages of agomelatin as an antidepressant associated with a low risk of sexual side effects are emphasized.

Effect of Loop Electrosurgical Excision Procedure on Sexual Dysfunction in Korean Women.

The role of the cervix in female sexual functioning is controversial. The loop electrosurgical excision procedure (LEEP) induces structural changes in the cervix. This study aimed to investigate whether LEEP affected sexual dysfunction in Korean women. A prospective cohort study enrolled 61 sexually active women with abnormal Papanicolaou smear or cervical punch biopsy results and required LEEP. The patients were assessed before and six to twelve months after LEEP using the Female Sexual Function Index (FSFI) and the Female Sexual Distress Scale (FSDS). The prevalence of female sexual dysfunction according to FSFI scores before and after LEEP was 62.5% and 66.7%, respectively. LEEP-related changes in total FSFI and FSDS scores were not significant (P = 0.399 and P = 0.670, respectively). The frequency of sexual dysfunction in the desire, arousal, lubrication, orgasm, satisfaction, and pain subdomains of the FSFI was not significantly altered by LEEP (P > 0.05). The proportion of women experiencing sexual distress according to FSDS scores did not significantly increase after LEEP (P = 0.687). A large proportion of women with cervical dysplasia experience sexual dysfunction and distress both before and after LEEP. LEEP itself may be not associated with negative effects on female sexual function.

Evaluation Of Morbid Obese Patients In Terms Of Sexual Dysfunctions: A Cross-Sectional Study

Aim: Obesity is a risk factor for sexual dysfunction. The aim of this study was to determine the frequency of sexual dysfunction in patients diagnosed with morbid obesity.Methods: The patient group included in the study consisted of 78 morbidly obese patients with BMI≥40 kg/m2 and 68 healthy individuals with normal BMI. The data were obtained by using the sociodemographic information form filled by the participants, Beck anxiety scale, Beck depression scale and Golombok Rust Sexual Satisfaction Inventory.Results: Obese individuals were found to have sexual dysfunction compared to individuals with normal body BMI (p&amp;lt;0.05). When the Golombok Rust subscale scores of obese men were compared to those of normal-weight individuals, a significant deterioration was found in all subscale scores, including frequency, communication, satisfaction, avoidance, touch, impotence and premature ejaculation. In addition, the anxiety and depression scores of obese individuals were shown to be higher than those of normal-weight individuals (p&amp;lt;0.05).Conclusion: Morbidly obese individuals should be evaluated in terms of sexual functions. We believe that regulating obesity treatment, including possible treatment for sexual dysfunction, will increase the success rate and enhance the quality of life for patients.

Sexual dysfunction in female and male patients undergoing chronic ambulatory peritoneal dialysis

To prolong survival and to provide a better quality of life (QoL) are two aims at the forefront in the care of peritoneal dialysis (PD) patients. In this study we aimed to determine frequency of sexual dysfunction (SD) and influencing factors in PD patients. Of the 201 patients, 114 under 65 years and on chronic ambulatory PD for at least 3 months were enrolled. Forty-nine females and 65 males completed the study. Survey forms were applied using face-to-face interview method. Female Sexual Function Index (FSFI) was used to assess SD in women; International Index for Erectile Function (IIEF) was used to assess erectile dysfunction (ED) in men. All patients completed SF-36 and Beck Depression Inventory (BDI) forms. While SD was evident in 89.8% of female patients (FSFI score:10.4 ± 9.7), ED was present in 87.7% of males (IIEF score:13.8 ± 7.9). Depression rates were 65.3% and 49.2% in female and male patients, respectively. BDI scores were 21.6 ± 10.4 and 17.1 ± 9.5; physical component scores, 52.6 ± 20.4 and 55.2 ± 20.2; mental component scores, 45.2 ± 19.8 and 49.9 ± 22, in female and male patients, respectively. FSFI was correlated with age (β = -0.53 p < 0.001) and BDI score (β = -0.23 p = 0.04), (R2 = 0.64). ED showed correlation with age (β = -0.36 p < 0.001), BDI score (β = -0.57 p < 0.001), and hemoglobin level (β = 0.26 p = 0.003), (R2 = 0.74). SD, often overlooked and not discussed by both patients and physicians, is encountered relatively frequently among PD patients. Left not discussed and untreated SD may adversely affect QoL.

Evaluation of sexual functional status and consistency of scales in patients with hypogonadotropic hypogonadism before and after testosterone replacement therapy: a single-center experience.

This study aimed to investigate the frequency of sexual dysfunction and the effect of short-term testosterone replacement therapy on sexual functions in congenital hypogonadism patients. Furthermore, we sought to reveal the consistency of the self-report scales used for the diagnosis of sexual dysfunction and the relationship between biochemical parameters. The study was conducted on 47 young male patients aged above 18 years who were diagnosed with hypogonadotropic hypogonadism. Short (IIEF-5) and long (IIEF-15) forms of the International Index of Erectile Function and Arizona Sexual Experiences Scale (ASEX) were applied before treatment under the supervision of a physician. The patients' blood pressure, height, and weight were measured, and their luteinizing hormone (LH), FSH, and total testosterone levels were recorded. Patients who started their treatments were called for a follow-up checkup after 6 months. Their blood pressure, height, and weight were measured by reapplying the ASEX, IIEF-5, and IIEF-15. In addition, their LH, FSH, and total testosterone levels in the biochemical tests were rerecorded. In this study, the sexual dysfunction status of patients diagnosed with hypogonadotropic hypogonadism before and after treatment was evaluated using the ASEX, IIEF-15, and IIEF-5 scales. A decrease in sexual dysfunction was observed in all three scales after treatment compared with that before treatment. The IIEF-5 and IIEF-15 scales were found to be uncorrelated in terms of the pretreatment values but were correlated in terms of the post-treatment values. Although a correlation was observed between ASEX and IIEF- 5 before treatment, no correlation was detected between ASEX and IIEF-15. After the treatment, ASEX was found to be correlated with both IIEF-5 and IIEF-15. The results of the scales indicated the correlation in all categories, except the pretreatment results of the IIEF-15 scale. The results of the current study demonstrated a significant improvement in the sexual function of hypogonadism patients undergoing short-term testosterone therapy. The ASEX, IIEF-5, and IIEF-15 scales used in the diagnosis and follow-up of sexual dysfunction were useful for evaluating sexual functions in hypogonadotropic hypogonadism patients.